RESUMO
Purpose@#A near-infrared (NIR) fluorescence imaging is a promising tool for cancer-specific image guided surgery. Human epidermal receptor 2 (HER2) is one of the candidate markers for gastric cancer. In this study, we aimed to synthesize HER2-specific NIR fluorescence probes and evaluate their applicability in cancer-specific image-guided surgeries using an animal model. @*Materials and Methods@#An NIR dye emitting light at 800 nm (IRDye800CW; Li-COR) was conjugated to trastuzumab and an HER2-specific affibody using a click mechanism. HER2 affinity was assessed using surface plasmon resonance. Gastric cancer cell lines (NCI-N87 and SNU-601) were subcutaneously implanted into female BALB/c nu (6–8 weeks old) mice.After intravenous injection of the probes, biodistribution and fluorescence signal intensity were measured using Lumina II (Perkin Elmer) and a laparoscopic NIR camera (InTheSmart). @*Results@#Trastuzumab-IRDye800CW exhibited high affinity for HER2 (KD =2.093(3) pM).Fluorescence signals in the liver and spleen were the highest at 24 hours post injection, while the signal in HER2-positive tumor cells increased until 72 hours, as assessed using the Lumina II system. The signal corresponding to the tumor was visually identified and clearly differentiated from the liver after 72 hours using a laparoscopic NIR camera. AffibodyIRDye800CW also exhibited high affinity for HER2 (KD =4.71 nM); however, the signal was not identified in the tumor, probably owing to rapid renal clearance. @*Conclusions@#Trastuzumab-IRDye800CW may be used as a potential NIR probe that can be injected 2–3 days before surgery to obtain high HER2-specific signal and contrast. Affibodybased NIR probes may require modifications to enhance mobilization to the tumor site.
RESUMO
BACKGROUND: Oxycodone is a strong m-opioid receptor agonist and has a longer duration of analgesic effect than fentanyl. We compared the use of an intravenous (IV) bolus of oxycodone and fentanyl for postoperative analgesic efficacy after dental surgery. METHODS: Patients underwent surgical extraction under general anesthesia. We prospectively enrolled patients who had received IV oxycodone (n = 36, 0.05 mg/kg) and fentanyl (n = 36, 1 mg/kg) 10 minutes before the end of surgery. The recovery profiles (hemodynamic variables, pain score, postoperative nausea and vomiting, sedation scale, and adverse events) were recorded for 1 hour in the post-anesthetic care unit (PACU) and at 6 hours after surgery. RESULTS: Under a potency ratio of 50:1 (oxycodone:fentanyl), time to spontaneous ventilation was significantly longer in the oxycodone group (8.1 ± 2.8 min vs. 6.9 ± 1.8 min, P = 0.021). The overall pain scores were significantly lower in the oxycodone than in the fentanyl group (P < 0.001), and the oxycodone group had significantly fewer additional analgesic requirements in the PACU than the fentanyl group (8.3% vs. 27.8%, P = 0.032). The incidence of postoperative nausea and sedation were comparable in both groups. No opioid-related adverse event was identified. CONCLUSIONS: In dental surgery, 0.05 mg/kg IV oxycodone had a longer-lasting analgesic effect than that of 1 µg/kg IV fentanyl, and could reduce total opioid consumption without increasing side effects. Patients experienced satisfactory analgesia postoperatively; thus, oxycodone is an effective opioid analgesic for acute postoperative pain relief.